ClinicalTrials.gg
Enrolling by invitationNCT07228702Updated Jun 3, 2026

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

A Phase 1 interventional study of Mycobacteriophage Muddy_HRMN0052 and Amikacin Injection in Non-Tuberculous Mycobacterial (NTM) Pneumonia and Mycobacterium Abscessus Infection, sponsored by Vancouver Coastal Health. Enrolling by invitation at 1 site in Canada. Open to female participants. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Vancouver Coastal Health · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Pneumonia with a site in Canada — 11 open to participants now, 13 under way, 4 of them phase 3. Pneumonia · Canada.

Planned enrollment
36th of 38
1 · median 201
Started
2026
with 3 others
Phase 1
Only one
of the 56
Primary completion
2027-10
later than 5 of 12 live
Registered
55th of 56
by date

Among the 56 studies in Pneumonia with a site in Canada, this one is the 36th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 55th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

11 of the 56 studies in Pneumonia with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Pneumonia with a site in Canada, or all of them as a file.
02

Study summary

This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease

Read the detailed description

Hypothesis

Hypothesis: Mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with MABS will reduce infection burden and improve pulmonary disease.

Objectives:

  1. Efficacy - Assess MABS pulmonary disease response mycobacteriophage therapy
  2. Safety - Determine tolerability and off target effects of IV and inhaled mycobacteriophage therapy

Specific End Points (during and post treatment up to last clinical follow-up (>24month):

  1. Microbiologic: Time to sputum smear and culture conversion; durability of sputum culture conversion during and post treatment; change in sputum microbiology on and post treatment; change in MABS drug and mycobacteriophage susceptibility on and post treatment; mycobacteriophage neutralizing antibody development.
  2. Clinical: Pulmonary and systemic symptom report; sputum production volume (patient report); chest imaging response (CT scan); Spirometry and full PFT; quality of life
  3. Other: Adverse clinical and laboratory events

Information on the Investigational Product (Mycobacteriophage Muddy_HRMN0052):

  1. Mechanism of action Bacteriophage therapy (phage therapy) involves the use of live, lytic bacteriophages to treat bacterial infections via bacterial cell lysis. Lytic bacteriophages mediate their antimicrobial effect by way of specific attachment to bacterial cell wall receptors, injection of bacteriophage DNA into the bacterium, recruitment of bacterial host cell machinery for bacteriophage protein production, and subsequent lysis of the bacterial cell with release of bacteriophage progeny.
  2. Dose, frequency, route of administration for the product

Initial IV dosing of Mycobacteriophage Muddy_HRMN0052 for treatment of Mycobacterium abscessus should be 1mL containing 1 x 10\^9 PFU/mL to be given IV twice daily.

Inhalation:

Initial inhaled (by nebulization or aerosolization) dosing of Mycobacteriophage Muddy_HRMN0052 for treatment of Mycobacterium abscessus should be 1mL containing 1 x 10\^9 PFU/mL to be given inhaled twice daily. For inhaled use, Mycobacteriophage Muddy_HRMN0052 is supplied in the lyophilized form that enhances the stability during nebulization.

The treatment duration for both routes of administration is expected to be between 16 to 24 weeks at minimum with a possible extension up to 24 months if necessary, based upon clinical response.

Treatment Regimen and Duration:

Initial IV dosing for treatment of Mycobacterium abscessus with Mycobacteriophage Muddy_HRMN0052 should be 1mL containing 1 x 10\^9 PFU/mL to be given IV twice daily.

Initial inhaled dosing for treatment of Mycobacterium abscessus with Mycobacteriophage Muddy_HRMN0052 should be 1mL containing 1 x 10\^9 PFU/mL to be given inhaled twice daily.

The duration of treatment to be determined based on clinical response, but the recommended initial course of treatment is expected to be at least 16-24 weeks and used together with antimicrobial therapy targeted at the infecting organism recovered from the patient. The duration and start timing of IV and inhaled formulation will be guided by tolerance and clinical response with potential transition to single route as treatment progresses.

If the inhaled route of administration is not tolerated by the patient, as determined by a drop in FEV1 percent predicted (FEV1pp) of greater than 20% from baseline with the first dosage, and/or intolerable symptoms of cough or shortness of breath that are not relieved with bronchodilator (salbutamol) with the first dose, or if respiratory symptoms develop with later dosing that are deemed intolerable by the patient, then the treatment will revert to IV administration.

Concurrent with MUDDY phage treatment the following antibiotics will be use. Use of phage plus antibiotics is similar to prior reported human treatment of NTM disease with mycobacteriophages and in line with Antibacterial Resistance Leadership Group (ARLG) Phage Taskforce (U.S.) guidance. To balance effectiveness and toxicity risk two antibiotics that Mycobacterium abscessus has been demonstrated susceptible to will be used. Selection of drugs is also informed by tolerance during prior treatment. Alternate medications will be used if toxicity from first choice antibiotics encountered. Antibiotics/rationale are as follows, all doses are standard weight-based dosing:

Initial Regimen:

  1. Amikacin 1000mg IV 3x/wk - prior good tolerance, evidence based preferred agent for treatment of NTM disease
  2. Clofazimine 100mg PO OD - prior good tolerance; general low toxicity profile, M. abscessus demonstrated to have favorable low MIC.

Alternate agents (use if toxicity/intolerance to initial regimen agents to ensure on 2 antibiotics throughout):

  1. Bedaquiline 400mg PO OD x 2 weeks then 200mg PO 3x/wk - prior good tolerance; general low toxicity profile, M. abscessus demonstrated to have favorable low MIC.
  2. Linezolid 600mg PO OD (dose reduce to 600mg PO 3x/wk if adverse effects) - unclear if contributed to prior anorexia while on multidrug regimen, risk of toxicity with extended use
  3. Sulfamethoxazole/Trimethoprim 800/160mg PO BID - less evidence available supporting use for M. abscessus disease, prior issues with associated hyperkalemia

AMENDMENT May 30, 2026:

Additional antibiotics to be used guided by follow-up drug susceptibilty testing (stopping medications that may show acquired resistance) and allowing up to 6 potentially effective antibiotic agents may include:

  1. Imipenem 1g IV Q12
  2. Ceftaroline 600mg IV Q12H
  3. Omadacycline 300mg PO BID
03

Conditions studied

  • Non-Tuberculous Mycobacterial (NTM) Pneumonia
  • Mycobacterium Abscessus Infection

Keywords

  • non-tuberculous mycobacteria
  • bacteriophage
  • mycobacteriophage
  • mycobacterium abscessus
  • pulmonary disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

This is an individual patient expanded access study specific to one individual based on tailor intervention (Mycobacteriophage)

Inclusion criteria

Inclusion Criteria:

  • consent to participation

Exclusion criteria

Exclusion Criteria:

  • non-consent to participation
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Experimental
    Treatment

    Use of mycobacteriophage

    Biological: Mycobacteriophage Muddy_HRMN0052 · Drug: Amikacin Injection · Drug: Clofazimine · Drug: Bedaquiline (B) · Drug: Linezolid (LZD) · Drug: Sulfamethoxazole/Trimethoprim · Drug: Imipenem + Cilastatin · Drug: Ceftaroline fosamil · Drug: Omadacycline Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Microbiologic: Response

    1\. Sputum culture status: time (days) to durable sputum culture conversion (no mycobacterial growth on 3 sputum sample)

    Time frame: 2 years

Secondary outcomes

  1. Microbiologic: Resistance development

    MABS drug and phage resistance development on follow-up sputum cultures (on treatment and post)

    Time frame: 2 years

  2. Microbiologic: Neutralizing antibody status.

    Detection of mycobacteriophage neutralizing antibodies on follow-up serology

    Time frame: 2 years

  3. Clinical: Symptoms

    Pulmonary and systemic symptom report change using adapted global assessment of quality of life. This will be patient reported and scored at each clinical assessment as follows and in reference/comparison to last/most recent score (negative = worse, positive = improved): * 4 Markedly Improved ( \>75% improved quality of life) * 3 Much Improved (51-75% improved quality of life) * 2 Improved (25-50% improved quality of life) * 1 Slightly Improved (1-24% improved quality of life) 0 No Change * 1 Slightly Worse (1-24% reduced quality of life) * 2 Worse (25-50% reduced quality of life) * 3 Much Worse (51-75% reduced quality of life) * 4 Markedly Worse (\>75 % reduced quality of life)

    Time frame: 2 year

  4. Clinical: Sputum

    sputum production volume change (patient report)

    Time frame: 2 year

  5. Clinical: Radiographic

    Chest imaging response (CT scan) to treatment

    Time frame: 2 year

  6. Clinical: Pulmonary Function

    Spirometry and full PFT changes on treatment

    Time frame: 2 year

  7. Clinical: Adverse effects

    Adverse clinical and laboratory events (number and severity) on treatment

    Time frame: 2 year

  8. Clinical: Symptoms

    Pulmonary and systemic symptom report change (Physicians Global Assessment to measure quality of life)

    Time frame: 2 year

07

Study locations

1 site
  • Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic
    Vancouver, British Columbia V5Z 1M9, Canada
08

References and documents

Publications

  • Reindel R, Fiore CR. Phage Therapy: Considerations and Challenges for Development. Clin Infect Dis. 2017 Jun 1;64(11):1589-1590. doi: 10.1093/cid/cix188. No abstract available. PubMed 28329182 ↗
  • Hatfull GF. Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities. Pulm Ther. 2023 Mar;9(1):91-107. doi: 10.1007/s41030-022-00210-y. Epub 2022 Dec 30. PubMed 36583829 ↗
  • Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, Whitney Brown A, Cohen KA, Davidson RM, van Duin D, Gainey A, Garcia CB, Robert George CR, Haidar G, Ip W, Iredell J, Khatami A, Little JS, Malmivaara K, McMullan BJ, Michalik DE, Moscatelli A, Nick JA, Tupayachi Ortiz MG, Polenakovik HM, Robinson PD, Skurnik M, Solomon DA, Soothill J, Spencer H, Wark P, Worth A, Schooley RT, Benson CA, Hatfull GF. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clin Infect Dis. 2023 Jan 6;76(1):103-112. doi: 10.1093/cid/ciac453. PubMed 35676823 ↗

Individual participant data

Plan to share: Undecided — Will depend on participant and institution agreement

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 35 phase 1 interventional studies under Pneumonia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Nov 14, 2025
StartActual
Jan 11, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07228702
Lead sponsor
Vancouver Coastal Health
Responsible party
William Connors (Clinical Associate Professor, Vancouver Coastal Health) — Principal investigator
First posted
Nov 14, 2025
Start date
Jan 11, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amikacin · Clofazimine · Bedaquiline · Linezolid · Sulfamethoxazole · Trimethoprim · Imipenem · Cilastatin · Ceftaroline · Omadacycline

Start the discussion